-+ 0.00%
-+ 0.00%
-+ 0.00%

ENDRA risks Nasdaq delisting after falling below $2.5 million equity requirement

PUBT·04/21/2026 12:01:49
Listen to the news
ENDRA risks Nasdaq delisting after falling below $2.5 million equity requirement
  • Nasdaq warned ENDRA Life Sciences on April 20, 2026 that it is out of compliance with Listing Rule 5550(b)(1) after reporting stockholders’ equity of 2,260,120 in its 2025 Form 10-K.
  • Staff letter said ENDRA faces delisting unless it requests a hearing before Nasdaq Hearings Panel.
  • ENDRA plans to request hearing, which would stay delisting action pending panel decision.
  • Company is evaluating steps to regain minimum 2,500,000 stockholders’ equity requirement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-045885), on April 21, 2026, and is solely responsible for the information contained therein.